Skip to main content

Biomea Fusion, Inc. (BMEA)

NASDAQ: BMEA · Delayed Price · USD
10.36
+0.36 (3.60%)
After-hours:Sep 21, 2021 5:40 PM EDT
10.00
-0.35 (-3.38%)
At close: Sep 21, 4:00 PM
Market Cap291.51M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out25.16M
EPS (ttm)-1.23
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume224,618
Open10.30
Previous Close10.35
Day's Range9.72 - 10.72
52-Week Range9.72 - 22.22
Betan/a
Analystsn/a
Price Target26.00 (+160.0%)
Est. Earnings DateNov 4, 2021

About BMEA

Biomea Fusion is a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. An irreversible small molecule drug is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional reversible drugs, including greater target selectivity, lower drug exposure and the ability to drive a deeper, more durable response. We built our proprietary FUSION ...

IndustryBiotechnology
IPO DateApr 16, 2021
CEOThomas Butler
Employees20
Stock ExchangeNASDAQ
Ticker SymbolBMEA
Full Company Profile

Financial Performance

Financial Statements

News

Biomea Fusion To Start Early-Stage Leukemia Setting Trial With BMF-219

The FDA has signed off Biomea Fusion Inc's (NASDAQ: BMEA) Investigational New Drug application to begin a Phase 1 trial of BMF-219, a selective irreversible menin inhibitor. The trial will include adult...

5 days ago - Benzinga

Biomea Fusion Announces FDA Clearance of Investigational New Drug Application for Irreversible Menin Inhibitor BMF-219

REDWOOD CITY, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a biopharmaceutical company focused on the discovery and development of irreversible small molecul...

5 days ago - GlobeNewsWire

4 Stocks Insiders Are Buying

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.

Other symbols:DNUTEOLSRFL
3 weeks ago - Benzinga

Biomea Fusion Reports Second Quarter 2021 Financial Results and Business Highlights

REDWOOD CITY, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a preclinical-stage biopharmaceutical company focused on the discovery and development of irreversi...

1 month ago - GlobeNewsWire

BIOMEA Fusion Strengthens its Executive Team with Appointment of Franco Valle as Chief Financial Officer

REDWOOD CITY, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a preclinical-stage biopharmaceutical company focused on the discovery and development of irreversi...

2 months ago - GlobeNewsWire

Biomea Fusion Reports First Quarter 2021 Financial Results and Business Highlights

-- Received $167 million in aggregate gross proceeds in  April from initial public offering -- – Advancing lead oncology program BMF-219, a small molecule irreversible menin inhibitor, toward IND filing...

3 months ago - GlobeNewsWire

2 Hot Biotech IPOs to Consider

These companies are already making great strides where few dare to tread.

Other symbols:RXRX
4 months ago - The Motley Fool

Biomea Announces Closing of Initial Public Offering

REDWOOD CITY, Calif., April 20, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a preclinical-stage biopharmaceutical company focused on the discovery, development and commercial...

5 months ago - GlobeNewsWire

Biomea Announces Pricing of Initial Public Offering

Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a preclinical-stage biopharmaceutical company...

5 months ago - GlobeNewswire

Biomea Fusion IPO Registration Document (S-1)

Biomea Fusion, Inc. has filed to go public with an IPO on the NASDAQ.

5 months ago - SEC